StockTipsArenaBeta

BUY Lupin Limited — Laxmikant Shukla, YES Securities

BUYLupin Limited
Lupin share price target & all analyst calls

byLaxmikant Shukla, YES SecuritiesHorizon: NA (inferred Swing (≤2wk))6 May 2026via ET Now

Entry₹2,400Stated
Target₹2,600
Total upside +8.33% (call closed)
Stop loss₹2,300-4.17% risk
Exit₹2,30011 May 2026, 9:15 am
Stop-loss hit-4.17%
Follow Laxmikant Shukla for new calls(29% target hit, 113 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 1 active Swing call on LUPINSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 10:49 pm IST
4 supporting1 neutral0 opposing
Supports the BUY call (4)

Lupin Limited announced its audited financial results for FY2026 and Q4 FY2026. The company reported a significant increase in sales and EBITDA, with a recommended dividend of 900%.

NSE · Press Release·7 May · 3d ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·6 May · 4d ago

Lupin Limited has received approval from the U.S. Food and Drug Administration (FDA) for its Glycerol Phenylbutyrate Oral Liquid.

BSE · Company Update·5 May · 6d ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·4 May · 6d ago

Neutral / worth noting (1)

The Audited Financial Results for the quarter and year ended March 31, 2026 and recommendation of Final Dividend of Rs. 18 /- per equity share i.e. 900 % of the Face Value of Rs. 2/- each ....

BSE · Board Meeting·7 May · 3d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from Laxmikant Shukla, YES Securities

Every call and its outcome